M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis

Launched by RDC CLINICAL PTY LTD · Mar 27, 2025

Keywords

ClinConnect Summary

The M-Gard Particulate EW Efficacy Study is a clinical trial designed to test a new supplement called M-Gard, which aims to help people with seasonal allergic rhinitis—often triggered by grass pollen—feel better during allergy season. The trial will evaluate how effective and safe this supplement is for alleviating allergy symptoms. It is important to note that the trial is not currently recruiting participants.

To participate, individuals must be adults aged 18 to 65 who are generally healthy and have a history of seasonal allergies to grass, confirmed by a specific allergy test. Participants should not have any serious health issues, should not be using certain medications that could affect their immune system, and must agree to maintain their current diet and exercise routine throughout the study. Those who join the trial will be monitored to see how M-Gard affects their allergy symptoms over time. This study will provide valuable information about a potential new way to manage seasonal allergies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18-65 years.
• • Generally healthy
• • Individuals with a history of recurrent seasonal allergic rhinitis
• • Positive RAST test for grass allergy
• • BMI 18-35kg/m2
• • Able to provide informed consent
• • Agree not to change current diet and/or exercise routine during entire enrolment period
• • Agree to not participate in another clinical trial during the study period
• Exclusion Criteria:
• • Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders, neurological disorders such as multiple sclerosis.
• • Unstable illness e.g., diabetes and thyroid gland dysfunction.
• • Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.
• • Individuals with symptomatic perennial allergic rhinitis, non-allergic rhinitis, chronic respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease).
• • Participants with cognitive damage.
• • Acute illness experienced in the past 1 month.
• • Active smokers and/or nicotine or drug abuse.
• • Allergic to any of the ingredients in the active or placebo formula.
• • Chronic past and/or current alcohol use (\>21 alcoholic drinks per week)
• • Attempting to conceive, pregnant or lactating women
• • Use of medications that would affect the immune and/or the inflammatory response e.g. immunotherapy, antihistamines (daily use), corticosteroids, mast cell stabilizers, leukotriene modifiers, and decongestants.
• • Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin; tricyclic antidepressants; Clonidine and other central acting alpha-2-agonists.
• • Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month.
• • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.